Researchers develop unique technology to overcome global antibiotic resistance crisis

NewsGuard 100/100 Score

A British nanotech company has created a potentially life changing technology that aims to overcome the global crisis of antibiotic resistance.

Researchers from AGA Nanotech ltd, working with University College London (UCL), have developed a unique alternative to antibiotics.

They have enabled the safe and effective delivery of antimicrobials which do not give rise to resistance. Borrowing approaches used in oncology, they have identified a means of delivering high energy oxidative molecules to the site of infection without harming the patient.

By loading particles produced by a Thermally Induced Phase Separation (TIPS) technique developed by Dr Richard Day at UCL, they have been able to use microparticles to direct the controlled delivery of antimicrobial agents straight to the site of infection.

The use of nanoplatforms allows the delivery of highly oxidative biocides directly to infecting bacteria without being toxic to the body. Unlike antibiotics, its unique properties allow it to overcome any antibiotic resistance the bacteria may have.
According to the World Health Organisation (WHO), antibiotic resistance is one of the biggest threats to global health. It can affect anyone, of any age, in any country.

It has also led to infections such as pneumonia, tuberculosis, blood poisoning, gonorrhoea, and foodborne diseases, becoming difficult and in sometimes impossible to treat as antibiotics become less effective.

The AGA Nanotech precursor loaded TIPS particles provide an innovative antimicrobial alternative to classic antibiotic agents and could serve as adjunctive or replacement therapy.

The first application from the company will be in the field of wound care, however the technology can be adapted for pulmonary, oral or systemic delivery. It offers great potential for the creation of bespoke approaches to different clinical conditions and also avoids the issue of continually bringing new expensive antibiotics to market.

AGA Nanotech was set up with the ultimate aim of overcoming the increasing problem of antibiotic resistance.

Their current technology incorporates precursors for hydrogen peroxide and peracetic acid within nanoparticles and microparticles. This approach is preferred because the inert precursors deliver highly reactive oxidative biocides, and hence do not give rise to resistance, but have low systemic toxicity and breakdown to give benign residues.

Adrian Fellows of AGA Nanotech said:

We can engineer biodegradable nanoparticles that have a broad range of physical and biological properties that can specifically target an organ or infection site, this is both novel and transformative.

Our research demonstrates that we can load precursor compounds, release them in a controlled way and convert them into oxidative species.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Reviving a rejected drug: New selective antibiotic shows promise